BRAFE600-associated senescence-like cell cycle arrest of human naevi

Nature

Volumn 436, Issue 7051, 2005, Pages 720-724

  Michaloglou, Chrysiis ^a   Vredeveld, Liesbeth C W ^a   Soengas, Maria S ^b   Denoyelle, Christophe ^b   Kuilman, Thomas ^a   Van Der Horst, Chantal M A M ^c   Majoor, Donné M ^a   Shay, Jerry W ^d   Mooi, Wolter J ^e   Peeper, Daniel S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Comprehensive Cancer Center ^*  (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; ENZYMES; GROWTH KINETICS; HUMAN ENGINEERING; ONCOLOGY; TUMORS;

ASSOCIATED SENESCENCE; CELL CYCLES; FINITE LIFESPAN; MALIGNANCY;

CELLS;

B RAF KINASE; BETA GALACTOSIDASE; GLUTAMIC ACID; PROTEIN P16INK4A; RAS PROTEIN; VALINE; BRAF PROTEIN, HUMAN;

BIOLOGY;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MAMMAL CELL; MELANOCYTE; NEVUS; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; TELOMERE; VALIDATION PROCESS; CELL AGING; CELL LINE; FIBROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; INFANT; METABOLISM; PATHOLOGY;

MAMMALIA;

BETA-GALACTOSIDASE; CELL AGING; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FIBROBLASTS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MELANOCYTES; NEVUS; PROTO-ONCOGENE PROTEINS B-RAF; TELOMERE;

EID: 23244447037     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03890     Document Type: Article

References (30)

1. Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614-636 (1965).
2. Mathon, N. F. & Lloyd, A. C. Cell senescence and cancer. Nature Rev. Cancer 1, 203-213 (2001).
3. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307-315 (2004).
4. Campisi, J. Senescent cells, tumour suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513-522 (2005).
5. Shay, J. W. & Roninson, I. B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23, 2919-2933 (2004).
6. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
7. Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nature Genet. 33, 19-20 (2003).
8. Kuwata, T., Kitagawa, M. & Kasuga, T. Proliferative activity of primary cutaneous melanocytic tumours. Virchows Arch. A Pathol. Anat. Histopathol. 423, 359-364 (1993).
9. Bennett, D. C. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22, 3063-3069 (2003).
10. Chin, L., Merlino, G. & DePinho, R. A. Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12, 3467-3481 (1998).
11. Robinson, W. A. et al. Human acquired naevi are clonal. Melanoma Res. 8, 499-503 (1998).
12. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
13. Wellbrock, C. et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342 (2004).
14. Mooi, W. J. & Krausz, T. Biopsy Pathology of Melanocytic Disorders 56-105 (Chapman & Hall Medical, London, 1992).
15. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367 (1995).
16. Sharpless, E. & Chin, L. The INK4a/ARF locus and melanoma. Oncogene 22, 3092-3098 (2003).
17. Zhu, J., Woods, D., McMahon, M. & Bishop, J. M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12, 2997-3007 (1998).
18. Lin, A. W. et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signalling. Genes Dev. 12, 3008-3019 (1998).
19. Narita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716 (2003).
20. Gruis, N. A. et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet. 10, 351-353 (1995).
21. Bandyopadhyay, D. et al. The human melanocyte: a model system to study the complexity of cellular aging and transformation in non-fibroblastic cells. Exp. Gerontol. 36, 1265-1275 (2001).
22. Wang, Y. L., Uhara, H., Yamazaki, Y., Nikaido, T. & Saida, T. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Br. J. Dermatol. 134, 269-275 (1996).
23. Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumour types. Science 264, 436-440 (1994).
24. Beausejour, C. M. et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22, 4212-4222 (2003).
25. Bastian, B. C. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 22, 3081-3086 (2003).
26. Miracco, C. et al. Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity. Br. J. Dermatol. 146, 399-408 (2002).
27. Peeper, D. S. & Mooi, W. J. Pathogenesis of melanocytic naevi: growth arrest linked with cellular senescence? Histopathology 41, S139-S143 (2002).
28. Patton, E. E. et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249-254 (2005).
29. Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M. & Tuveson, D. A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63, 5198-5202 (2003).
30. Peeper, D. S. et al. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nature Cell Biol. 4, 148-153 (2002).